Table 1.

Association between CD45RO⁺ratio and clinicopathological characteristics.

	CD45RO+ratio
	<1.07	≥1.07
Variables	n=95	n=90	P value
Sex
Male	57 (60.0%)	53 (58.9%)	.878
Female	38 (40.0%)	37 (41.1%)
Age (yrs)
<60	65 (68.4%)	60 (66.7%)	.799
≥60	30 (31.6%)	30 (33.3%)
Distance from anal verge (cm)
<5	37 (38.9%)	35 (38.9%)	.993
≥5	58 (61.1%)	55 (61.1%)
pre-CRT CEA level (ng/mL)
<5	47 (49.5%)	47 (52.2%)	.709
≥5	48 (50.5%)	43 (47.8%)
Tumour differentiation
G1-2	58 (61.1%)	68 (75.6%)	.034
G3-4	37 (38.9%)	22 (24.4%)
Clinical stage
II	29 (30.5%)	26 (28.9%)	.808
III	66 (69.5%)	64 (71.1%)
Surgery
Anterior resection	61 (64.2%)	65 (72.2%)	.243
Nonanterior resection	34 (35.8%)	25 (27.8%)
TRG
TRG0-1	21 (22.1%)	32 (35.6%)	.043
TRG2-3	74 (77.9%)	58 (64.4%)
ypT
T0	6 (6.3%)	3 (3.3%)	.001
T1–2	21 (22.1%)	42 (46.7%)
T3–4	68 (71.6%)	45 (50.0%)
ypN
N0	50 (52.6%)	60 (66.7%)	.052
N1–2	45 (47.4%)	30 (33.3%)
ypTNM stage
ypCR	9 (9.5%)	11 (12.2%)	.012
I	16 (16.8%)	33 (36.7%)
II	27 (28.4%)	19 (21.1%)
III	43 (45.3%)	27 (30.0%)
LVI
Negative	82 (86.3%)	80 (88.9%)	.596
Positive	13 (13.7%)	10 (11.1%)

CEA= carcinoembryonic antigen, CRT = chemoradiotherapy, LVI = lymphovascular invasion.

CD45RO⁺ratio-high was associated with lower tumor regression grade grading (P = .031), T stage (P = .001), and TNM stage (P = .012).